CAS: 583840-03-3; 4-(4-(3-(4-Chloro-3-(Trifluoromethyl)Phenyl)Ureido)Phenoxy)-2-(Methylcarbamoyl)Pyridine 1-Oxide

上下游产品

sorafenib

📜索拉非尼置于间氯过氧苯甲酸体系中,用 四氢呋喃,二氯甲烷 作为反应溶剂,化学反应 33.0H,以293 Mg的收率获得产物索拉非尼 N-氧化物
参考文献:Aryl Ureas As Kinase Inhibitors
标题:Aryl Ureas As Kinase Inhibitors
摘要:这项发明涉及新的芳基脲类化合物及其合成方法.这些创新化合物在治疗(I) 由raf介导的疾病,例如癌症,(II) 由p38介导的疾病,如炎症和骨质疏松症,以及(Iii) 由vegf介导的疾病,如血管反应生成紊乱方面具有用处.

专利信息

专利号:US-2025289827-A1
优先权日:2022-12-02
标 题:Morphic forms of a mutant braf degrader and methods of manufacture thereof
发明人：YU ROBERT T; HE MINSHENG; SCHNADERBECK MATTHEW J; KREGER BRIDGET; POLLOCK ROY MACFARLANE; JIANG SIYI; LI MEIQI; CHEN BOLU; LU JIANNAN
权利人:C4 THERAPEUTICS INC
摘要:Advantageous isolated morphic forms of (3R)-3-[6-[2-cyano-3-[[ethyl(methyl)sulfamoyl]amino]-6-fluorophenoxy]-4-oxoquinazolin-3-yl]-8-[2-[1-[3-(2,4-dioxo-1,3-diazinan-1-yl)-5-fluoro-1-methylindazol-6-yl]-4-hydroxypiperidin-4-yl]acetyl]-1-oxa-8-azaspiro[4.5]decane (Compound 1), which is a mutant BRAF degrader, and methods to prepare Compound 1 morphic forms for therapeutic applications are provided in the invention. The invention also provides improved methods for the synthesis of Compound 1, new pharmaceutical compositions comprising Compound 1, and new uses of Compound 1.

专利号:US-9181188-B2
优先权日:2002-02-11
标 题:Aryl ureas as kinase inhibitors
发明人：DUMAS JACQUES; SCOTT WILLIAM J; CHIEN DU-SCHIENG; NASSAR ALA; LEE WENDY; BJORGE SUSAN; MUSZA LASZLO L; RIEDL BERND
权利人:DUMAS JACQUES; SCOTT WILLIAM J; CHIEN DU-SCHIENG; NASSAR ALA; LEE WENDY; BJORGE SUSAN; MUSZA LASZLO L; RIEDL BERND; BAYER HEALTHCARE LLC
摘要:This invention relates to new aryl ureas and methods for their synthesis. The inventive compounds are useful in the treatment of (i) raf mediated diseases, for example, cancer, (ii) p38 mediated diseases such as inflammation and osteoporosis, and (iii) VEGF mediated diseases such as angiogenesis disorders.